NLS Pharmaceutics (NLSP) Stock Price, News & Analysis

Company Overview

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

Key Stats

• Today's Range: $3.11 to $3.55
• 50-Day Range: $0.13 to $5.34
• 52-Week Range: $3.00 to $29.08
• Volume: 66,411 shs
• Average Volume: 623,797 shs
• Market Capitalization: $12.57 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NLS Pharmaceutics Stock Analysis - MarketRank™

NLS Pharmaceutics scored higher than 24% of companies evaluated by MarketBeat, and ranked 854th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for NLS Pharmaceutics.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

NLS Pharmaceutics has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.27% of the float of NLS Pharmaceutics has been sold short.

Short Interest Ratio / Days to Cover

NLS Pharmaceutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NLS Pharmaceutics has recently decreased by 56.37%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NLS Pharmaceutics does not currently pay a dividend.

Dividend Growth

NLS Pharmaceutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.27% of the float of NLS Pharmaceutics has been sold short.

Short Interest Ratio / Days to Cover

NLS Pharmaceutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NLS Pharmaceutics has recently decreased by 56.37%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: N/A

News Sentiment

NLS Pharmaceutics has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for NLS Pharmaceutics this week, compared to 0 articles on an average week.

Search Interest

2 people have searched for NLSP on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NLS Pharmaceutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.40% of the stock of NLS Pharmaceutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

NLSP Stock Analysis - Frequently Asked Questions

How have NLSP shares performed this year?

NLS Pharmaceutics' stock was trading at $0.5899 at the beginning of the year. Since then, NLSP shares have increased by 457.7% and is now trading at $3.29.
View the best growth stocks for 2024 here.

When did NLS Pharmaceutics IPO?

NLS Pharmaceutics (NLSP) raised $20 million in an initial public offering (IPO) on Friday, January 29th 2021. The company issued 3,600,000 shares at $5.00-$6.00 per share. Maxim Group LLC served as the underwriter for the IPO and Brookline Capital (A division of Arcadia Securities) was co-manager.

How do I buy shares of NLS Pharmaceutics?

Shares of NLSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of NLS Pharmaceutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NLS Pharmaceutics investors own include Intel (INTC), Meta Platforms (META), Immunic (IMUX), Seres Therapeutics (MCRB), NVIDIA (NVDA), Palantir Technologies (PLTR) and Tesla (TSLA).

Company Calendar

• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NLSP
• CUSIP: N/A
• CIK: 1783036
• Web: www.nlspharma.com
• Phone: 41-44-512-2150
• Fax: 41-41-618-8009
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.15
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.14 per share
• Price / Book: 0.30

Miscellaneous

• Outstanding Shares: 3,815,000
• Free Float: 3,189,000
• Market Cap: $12.55 million
• Optionable: Not Optionable
• Beta: -0.51